The Strategic API Reserve, the federal stockpile of drug ingredients

At the end of 2025, a federal reserve of active pharmaceutical ingredients (APIs), the chemically active part of a medicine, received its first new deliveries under an order signed about four months earlier. The Administration for Strategic Preparedness and Response (ASPR) told Congress in its fiscal 2027 budget justification⁴ that "the first instance of the SAPIR became operational in late December 2025," and that it expected to secure "all the required quantities for the most critical essential medicines" by spring 2026. A later ASPR blog post⁵ dated the "placement of the first APIs" to the end of 2025.

SAPIR stands for the Strategic Active Pharmaceutical Ingredients Reserve. Executive Order 14336¹, signed Aug. 13, 2025, described the reserve as "nearly empty" and ordered ASPR to fill it with a six-month supply of ingredients for about 26 critical drugs.

It is a small program built on a large bet, that the US can cushion itself against foreign supply shocks by stockpiling raw drug ingredients instead of finished pills and vials.

What the reserve holds, and why ingredients

Most stockpiles store finished products. The Strategic National Stockpile, also run by ASPR, holds medical countermeasures and supplies ready to ship in an emergency. SAPIR stores the ingredient one step earlier in the chain. The executive order gives the rationale in two sentences. "Stockpiling APIs is advantageous as APIs are generally lower-cost and have longer shelf lives than the finished drug products they make," and filling the reserve would "insulate the United States from the concentration of foreign, sometimes adversary, nations" in the supply of key starting materials. GxRadar's piece on China's role in drug ingredients looks at the biggest of those sources.

Executive Order 14336 also put numbers on the dependence it wants to reduce. "Nearly two in five prescription finished drug products are made in the United States," it says, but "only about 10 percent of the APIs by volume for the finished drug products used in the United States are made here." GxRadar's explainer on where drug ingredients come from looks at the FDA facility data behind figures like these.

An ingredient in a drum cannot treat anyone. ASPR's budget document⁴ says the program covers "the procurement, storage, management, conversion, and distribution of qualified APIs from FDA-inspected suppliers with Drug Master Files on record," along with testing to accept and retest the material and "storage, rotation, and replenishment of APIs" under current good manufacturing practice. In plain terms, someone has to turn the stored powder into tablets or injections when it is needed, and the reserve's value depends on that conversion step working.

What Executive Order 14336 requires

Published in the Federal Register on Aug. 19, 2025 (90 FR 40223²), the order set a run of deadlines for ASPR. GxRadar computed the calendar dates from the signing date.

Every purchase in the order is "subject to the availability of funds," and the order told the Office of Management and Budget to help HHS repurpose existing money. It also expressed "a preference for obtaining domestically manufactured APIs if possible," which leaves room for imported ingredients when no US source exists. The White House fact sheet³ issued the same day summarized the same targets.

Where the list of medicines came from

SAPIR builds on two earlier lists. In August 2020, Executive Order 13944 directed FDA to identify essential medicines, medical countermeasures and critical inputs. FDA published that list in October 2020 (its later history is in FDA's essential medicines list, and what happened to it), focused on drugs "most needed for patients in U.S. acute care medical facilities," according to the agency⁷. The list itself⁸ runs from famotidine and heparin to amiodarone and ondansetron, mostly marked "API only" in its critical-inputs column. ASPR later cut it to 86 essential medicines in 2022, the order says.

A May 2025 order, Executive Order 14293⁹, separately told FDA to review and streamline its rules for inspecting and approving new domestic drug plants, citing industry estimates that new capacity "may take as long as 5 to 10 years" to build. ASPR's budget document cites both orders as the basis for its supply chain work.

ASPR has not published the roughly 26 drugs it chose. Its Sept. 21, 2026 update⁵ described the reserve's contents by class only, saying it had "secured initial supplies of critical APIs" for analgesics, antibiotics, reversal agents, hormones, bronchodilators and corticosteroids. APIs for additional medicines, including anticoagulants, were "being evaluated and prioritized for future acquisition." The update did not say whether the full six-month quantities had been reached.

How much money is behind it

Money for the reserve sits inside a small budget line. ASPR's Pandemic Preparedness and Biodefense program, run by its Center for Industrial Base Management and Supply Chain (IBMSC), received $10 million a year in fiscal 2024, 2025 and 2026, according to the funding history in the budget justification⁴. For fiscal 2027 the administration asked for $327 million, an increase of $324.6 million over the comparably adjusted 2026 level, to support "operation and maintenance costs" of the reserve and other onshoring work. The request also asked Congress to make the money available until spent, rather than for two years.

That request is a proposal. Congress sets the final number in appropriations. For scale, ASPR says⁴ IBMSC invested more than $18 billion in supplemental funding from fiscal 2020 through 2023 across drug manufacturing, testing and personal protective equipment. Separate from the reserve, ASPR's IBMSC office⁶ runs manufacturing projects, and the September update said its ReShoreRx effort works with 14 industry partners on domestic production for more than 30 critical medicines. Our piece on the federal onshoring push covers that wider effort.

What a stockpile can and cannot fix

FDA's own shortage data suggest where an ingredient reserve could help and where it would not. Of the 69 drugs FDA listed in current shortage on Oct. 30, 2026, five cited a "shortage of an active ingredient" as the reason, by GxRadar's count of the agency's shortage records¹⁰. Fifteen cited a demand increase and three cited manufacturing quality problems. Forty-nine of the 69 were injections, a form that depends on sterile fill-and-finish capacity rather than ingredient supply alone. Our shortage tracker lists them, and our explainer on sterile injectable shortages covers why that dosage form keeps reappearing.

Consider the 2024 IV fluid shortage. After a hurricane shut a major plant, the problem was finished-product capacity. ASPR's budget document says it arranged 98 flights carrying about 13.9 million units of imported IV solutions, as our account of that shortage also describes. A reserve of ingredients would not have filled those bags. For readers affected by a current shortage, our guide to questions to ask a pharmacist or prescriber is a better starting point than the reserve.

Congress's fiscal 2027 appropriation for ASPR is the next public checkpoint. It will show whether the reserve keeps running on a $10 million line or moves to the $327 million the budget requested. The order also asked for a plan to open a second repository within a year of Aug. 13, 2025. No public ASPR document GxRadar found says whether one has opened.